Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | ACP1 | P24666 | 2/20 | 0.43 |
| ▸ | PTPRF | P10586 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908732 | 1.00 | GPBAR1 (0.52) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL13908800 | 1.00 | GPBAR1 (0.52) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL10061314 | 1.00 | GPBAR1 (0.52) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL14134458 | 0.86 | SLC10A1 (0.52) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL15202809 | 0.86 | GPBAR1 (0.50) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL17761431 | 0.86 | GPBAR1 (0.50) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL13403269 | 0.86 | GPBAR1 (0.50) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL10061168 | 0.86 | GPBAR1 (0.59) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL16511700 | 0.86 | GPBAR1 (0.59) | GPBAR1LMNASMN1; SMN2NT5EPRKCD | |
| SCHEMBL17761427 | 0.85 | GPBAR1 (0.52) | GPBAR1LMNASMN1; SMN2NT5EPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | GPBAR1 3675/4885LMNA 2154/4885SMN1; SMN2 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.